Clinical Trial Update: Rifaximin in Fatty Liver Disease [Phase 4]

View source ↗

Summary

Phase 4 trial of rifaximin for fatty liver disease was terminated; results posted but status terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Imperial College London | Conditions: Nonalcoholic Fatty Liver Disease, NAFLD | Phase 4 | Status: TERMINATED | Results posted: 2020-09-04